Pharmaceutical Diversion Red Flags: An AML Guide for Kenya

Pharmaceutical diversion is the movement of legitimately manufactured medicines out of the regulated supply chain and into illicit markets. Opioid painkillers, sedatives and the precursor chemicals used to make synthetic drugs are the products most at risk, and East Africa is not insulated from the trade. The businesses best placed to spot diversion early are not only wholesalers but also the banks that process their payments and the lawyers and accountants who set up their companies. This guide sets out the warning signs at the pattern level, explains who has legal duties to act on them in Kenya, and describes what a sound response looks like.

Why Diversion Is a Legal Problem, Not Just a Commercial One

Under the Narcotic Drugs and Psychotropic Substances (Control) Act (Cap. 245), “trafficking” includes importing, exporting, storing, supplying and distributing narcotic drugs or psychotropic substances. Licensed activity carried out in accordance with the licence is excluded. Activity outside the licence is not. A wholesaler whose stock leaks to unauthorised buyers can therefore find that what began as a stock-control failure is treated as trafficking, with the severe penalties in section 4 of the Act. Section 4A creates separate offences for precursor chemicals.

The Pharmacy and Poisons Act (Cap. 244) adds its own exposure. Section 49 makes every director, secretary and manager of a company liable for the company’s offences under that Act unless they prove they did not consent or connive and that they exercised proper diligence.

Who Has Reporting Duties

The Proceeds of Crime and Anti-Money Laundering Act (POCAMLA) places monitoring and reporting duties on “reporting institutions”. Under section 44, a reporting institution must monitor complex, unusual, suspicious and large transactions and must report suspicious or unusual transactions or activities to the Financial Reporting Centre. Section 45 requires it to identify and verify its customers.

Banks and other financial institutions are reporting institutions. So are the designated non-financial businesses and professions listed in section 2, which, as the Act now reads, include accountants, trust and company service providers, and advocates, notaries and other independent legal professionals. Section 44(3A) preserves legal professional privilege: lawyers are not required to report information obtained in circumstances where professional secrecy or privilege applies.

Pharmaceutical wholesalers are not themselves listed as designated businesses. Their obligations come mainly from their licences and from Cap. 244 and Cap. 245: keeping prescribed records, supplying only authorised persons and cooperating with inspections. In practice, though, a wholesaler that ignores red flags will soon find its bank asking the questions for it.

Red Flags at Onboarding

For advisers and banks setting up or onboarding a pharmaceutical business, the warning signs usually appear before any product moves:

• Opaque identity. No named operating company, personal email addresses only, reluctance to identify beneficial owners, or messaging-app contact in place of an office.
• Product-first enquiries. A request that leads with a specific high-risk controlled medicine rather than with a business plan, customer base or therapeutic portfolio.
• Licence shopping. Interest in acquiring an existing licensed entity quickly, rather than building a compliant business, combined with little interest in its staff or operations.
• Nominal pharmacists. Questions about whether a local pharmacist can “hold” shares or a licence while others run the business. See our guide to name-lending pharmacists.
• Unexplained funding. Capital from unrelated third parties or jurisdictions with no connection to the stated business.

Red Flags in Trading

Once a business is operating, warning signs shift to its transactions:

• volumes of a controlled medicine that exceed what the stated customer base could plausibly use;
• customers who are not licensed pharmacies, hospitals or other authorised recipients;
• payments in cash, through third parties or from accounts unconnected with the customer;
• frequent stock “losses”, write-offs or register discrepancies for the same products;
• pressure to deliver quickly, to unusual locations, or without the usual documentation.

None of these proves diversion on its own. Together they call for enquiry, documentation and, where a reporting institution’s duties are engaged, a report.

Responding Properly

For reporting institutions, the response is structured by POCAMLA. Enhanced due diligence should be applied, the reasons for any suspicion recorded, and a report made to the Financial Reporting Centre where the section 44 threshold is met. Section 8 makes tipping off an offence: a person who knows a report is being prepared or has been made must not disclose information about it. Section 8(4) clarifies that a lawyer seeking to dissuade a client from illegal activity does not commit that offence.

The practical lesson for advisers is to keep first responses neutral. A request for standard due diligence documents, sent to every prospective client in the same way, protects the firm without signalling suspicion. For wholesalers, the answer is controls: verified customer licences, volume limits tied to realistic demand, frequent reconciliation of controlled-substance registers and clear escalation to the superintendent and board. Our guide to importing narcotic and psychotropic medicines into Kenya explains the licensing framework those controls sit within.

Frequently asked questions

This article is general information on Kenyan law as at its publication date, not legal advice. Reading it does not create an advocate and client relationship.